Objective: To analyze the clinical distribution and antimicrobial resistance of bloodstream infections (BSI) caused by Klebsiella pneumoniae, so as to provide evidence for clinical empirical use of antibiotics. Methods: Data of 332 Klebsiella pneumoniae isolates from BSI patients in Xuzhou Medical University Affiliated Hospital from January 2013 to December 2017 was analyzed retrospectively, including patients’ clinical data, antimicrobial susceptibility test, ESBLs phenotype confirmation as well as drug resistance phenotype of carbapenem. Results: A total of 332 strains of Klebsiella pneumoniae were isolated from the blood of patients, mainly from ICU (21%), EICU(18%) and infectious disease department (8%). The antibiotic resistance rate of Klebsiella pneumoniae to amikacin and carbapenems was relatively low in 5 years (20% and 30%, respectively); 137 ESBL-producing strains were isolated, accounting for 42.55%,whose drug resistance rate of common antibacterial drugs was significantly higher than that of non-ESBL-producting strains (P<0.01). Carbapenem-resistant strains isolated were 99 strains, accounting for 27.4%. The drug resistance rate of common antimicrobial strains was higher than that of Carbapenem-sensitive strains (P<0.01). The drug resistance rate of tetracycline, tobramycin, amikacin and compound xinomin was lower, 26.3%, 68%, 37.4% and 57.1%, respectively. Conclusion: Klebsiella pneumoniae BSI was mainly found in the ICU, EICU and infectious diseases department in this hospital during 2013 and 2017, the resistant rate of which to carbapenem and amikacin were relatively low. Carbapenem-resistant strains were still relatively sensitive to tetracycline, tobramycin, amikacin and sulfamethoxazole.